[
  {
    "ts": null,
    "headline": "Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?",
    "summary": "Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.",
    "url": "https://finnhub.io/api/news?id=2440f4d3266828617b44e82c39c5758131522f9145147a19bb291146cb198034",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765479820,
      "headline": "Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?",
      "id": 137760498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Noubar Afeyan says American hesitation is creating a strategic opening China is moving fast to exploit.",
      "url": "https://finnhub.io/api/news?id=2440f4d3266828617b44e82c39c5758131522f9145147a19bb291146cb198034"
    }
  },
  {
    "ts": null,
    "headline": "CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?",
    "summary": "CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.",
    "url": "https://finnhub.io/api/news?id=86aa4e991b6f249e02434944a5c96ae20e8685f35be59915fff2580cb9556815",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765468620,
      "headline": "CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?",
      "id": 137759836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.",
      "url": "https://finnhub.io/api/news?id=86aa4e991b6f249e02434944a5c96ae20e8685f35be59915fff2580cb9556815"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer plans job cuts in Switzerland to reduce expenses",
    "summary": "The cuts follow a broader downgrading of the drug manufacturer’s Swiss operations.",
    "url": "https://finnhub.io/api/news?id=959ec3ca0ab3461c5eb4d198d7ed85b0a913fe0c06c7e4712a7e36d6115b1c66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765465792,
      "headline": "Pfizer plans job cuts in Switzerland to reduce expenses",
      "id": 137758014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The cuts follow a broader downgrading of the drug manufacturer’s Swiss operations.",
      "url": "https://finnhub.io/api/news?id=959ec3ca0ab3461c5eb4d198d7ed85b0a913fe0c06c7e4712a7e36d6115b1c66"
    }
  },
  {
    "ts": null,
    "headline": "GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?",
    "summary": "GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.",
    "url": "https://finnhub.io/api/news?id=fa824c73af7e408e8ee311994eaec1288b2a5adb3fef507aceb50cd42ff41593",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765462320,
      "headline": "GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?",
      "id": 137758751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.",
      "url": "https://finnhub.io/api/news?id=fa824c73af7e408e8ee311994eaec1288b2a5adb3fef507aceb50cd42ff41593"
    }
  },
  {
    "ts": null,
    "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
    "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
    "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765457340,
      "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
      "id": 137757905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
      "url": "https://finnhub.io/api/news?id=459633750c779e958ca55188494098065f13895a77f80751d607045aecd2558c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients […]",
    "url": "https://finnhub.io/api/news?id=3c948ea613b84630613cb1ad66452a7a40c53185a29d56fc00e5c2b2e4c2e988",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765456379,
      "headline": "Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study",
      "id": 137757024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the Cheap NYSE Stocks to Buy Now. On December 6, Pfizer Inc. (NYSE: PFE) announced results from its Phase 3 BASIS Study, which evaluates HYMPAVZI for people living with hemophilia A or B with inhibitors. The study included 48 adults and adolescents with severe hemophilia A or B. Patients […]",
      "url": "https://finnhub.io/api/news?id=3c948ea613b84630613cb1ad66452a7a40c53185a29d56fc00e5c2b2e4c2e988"
    }
  },
  {
    "ts": null,
    "headline": "IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma",
    "summary": "IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free",
    "url": "https://finnhub.io/api/news?id=e4e7279119eebd1327209640e7213d177874a5e1e1821f2044b469d61a887efd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765450800,
      "headline": "IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma",
      "id": 137757025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free",
      "url": "https://finnhub.io/api/news?id=e4e7279119eebd1327209640e7213d177874a5e1e1821f2044b469d61a887efd"
    }
  },
  {
    "ts": null,
    "headline": "Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience",
    "summary": "Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.",
    "url": "https://finnhub.io/api/news?id=6b3540eb8985d41f895cd697fed37777b0722c89fbe664732df4d79b3f597393",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765442751,
      "headline": "Ex-Pfizer executive joins Elevance’s board as insurer pursues pharmacy experience",
      "id": 137758844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amy Schulman is the second veteran of the pharmaceutical industry that Elevance has added to its board this year.",
      "url": "https://finnhub.io/api/news?id=6b3540eb8985d41f895cd697fed37777b0722c89fbe664732df4d79b3f597393"
    }
  },
  {
    "ts": null,
    "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
    "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
    "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765438786,
      "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
      "id": 137759190,
      "image": "https://image.cnbcfm.com/api/v1/image/108198080-1757684463529-gettyimages-2177418373-20240909_cpupo_remedios_0832.jpeg?v=1757684482&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
      "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating",
    "summary": "Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...",
    "url": "https://finnhub.io/api/news?id=bae83241a41d8d98f052ffcb8dd8a9ed56b15f2f1262edf95884d0054637cb8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765429708,
      "headline": "How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating",
      "id": 137756011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...",
      "url": "https://finnhub.io/api/news?id=bae83241a41d8d98f052ffcb8dd8a9ed56b15f2f1262edf95884d0054637cb8e"
    }
  }
]